FDA's Cardio-Renal Drugs Advisory Committee will address all organic nitrates for long-term treatment of angina at its next meeting, scheduled for Jan. 26-27 at Jack Masur Auditorium on the NIH campus. The meeting is likely to include a discussion of efficacy data for transdermal nitroglycerin patches. Three patch marketers, Schering (Key's Nitro-Dur), Ciba-Geigy (Transderm-Nitro) and Searle (Nitro-disc), jointly sponsored a study to look at the efficacy of nitroglycerin patches....
You may also be interested in...
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.